Glioblastoma (GBM) tumour cells extensively infiltrate the brain [1] . Additionally, subsets of tumour cells develop a hyper-aggressive cancer stem cell (CSC) phenotype that enables resistance to radiological and chemical therapies [2] . CSCs also establish pro-tumourigenic relationships between each other as well as with the non-transformed cells present within their immediate zones of growth. The inherent complexity and adaptability [3] that derive from these features combine to make GBM the most common and most lethal primary adult brain cancer [4] . Our long-standing clinical standard of care comprises gross neurosurgical resection and adjuvant chemotherapy and radiotherapy [5] . This strategy effectively targets the primary tumour mass as well as a fraction of highly proliferative tumour cells, but leaves behind residual [6] infiltrative CSCs that evade treatment and ultimately serve as the seeds of disease recurrence and patient mortality. This strategy does not sufficiently account for the complexity of GBM, and represents little more than a short-term, palliative measure. In order to design a more effective treatment paradigm, we must address this complexity head on. This will involve identifying CSC populations and revealing the full set of their interactions.
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New research published by Shiraki et al in the Journal of Pathology has offered fresh insights into the identity and behaviour of a population of GBM CSCs that tend to grow along blood vessels [7] . The authors used primary human tumour tissue specimens and the RCAS/Tv-a genetically engineered mouse model of GBM to identify a population of perivascular CSCs that express the GPI-anchored protein CD109. These authors also demonstrated an interesting, pro-tumourigenic interaction between blood vessel-adjacent CD109 + CSCs and slightly more distal CD109 -NSTCs ( Figure 1A) . With this Commentary, we highlight this report and place it into the larger context of published information about niche-specific CSC populations. We also offer a brief synopsis of the landscape of interacting cell types within the GBM tumour microenvironment. This branch of GBM research has primarily focused on tumour cells interacting with non-transformed neural cell populations, but we also touch on the few reported examples of tumour cell cooperative interactions such as that revealed by Shiraki et al [7] . Numerous articles Perivascular CSCs drive non-stem tumour cell proliferation 261 have helped to refine our understanding of the molecular identity of CSCs in various anatomical niches. A second set of studies has shaped our understanding of tumour cell interactions. This report is a unique hybrid that shows the complexity of GBM at both of these levels, offering information on the molecular identity of a population of GBM CSCs, as well as describing a novel, pro-tumourigenic interaction that potentially drives disease progression.
Niche-specific CSC populations
CSCs become enriched in at least four anatomically distinct growth zones within the brains of GBM patients. Three of these niches, the subarachnoid, perineuronal and perivascular niches, were first described nearly 80 years ago by the Belgian neuropathologist Hans Scherer [8] , and are now referred to as the secondary structures of Scherer [9] . The fourth CSC-enriched niche is the hypoxic microenvironment established by insufficient tumour vasculature and the pseudopalisading necrotic structures that feature prominently throughout GBM tumours. Whereas Shiraki et al [7] focus specifically on the CSCs of the perivascular niche, a brief exploration of CSC populations in other niches is worthwhile, especially considering the problem of multiple CSC populations existing in a single GBM tumour [10] .
Hypoxic/perinecrotic growth zones are typically found within the main tumour mass, and are anatomically distant from the perivascular niche. The biology of hypoxia-inducible factors (HIFs) dominates our understanding of these niches. Multiple laboratories have established that, for GBM, overexpression and stabilization of primarily HIF2α drives the expression of several factors that maintain cellular pluripotency and the CSC phenotype. Multiple molecular mechanisms have been described that account for the persistent expression of HIF2α even in the presence of abundant oxygen [11, 12] within GBM CSCs. HIF1α may play a similar role; however, conflicting reports point to HIF1α activity in both the CSC [13] and non-stem tumour cell (NSTC) [14] fractions. Hypoxic/perinecrotic CSCs also express minimal levels of multiple Toll-like receptors (TLRs), including TLR4 [15] . This CSC-specific adaptation effectively shields this population from the growth-inhibitory effects of damage signalling within these otherwise inhospitable growth zones.
The perineuronal niche, also referred to as the intrafascicular or invasive niche, is located distal to the primary tumour mass. This growth zone is defined by the myelinated fibre tracts that make up the primary anatomy of the brain. The tumour cells residing here can present as either collective tendrils or as a diffuse array of individual cells loosely patterned on established white matter pathways. Classic work suggested that invasive glioma cells may be uniquely suited to the invasive niche because of an intrinsic capacity for myelin proteolysis [16] . Although relatively little is known about the CSC populations of the invasive niche, Siebzehrubl et al reported that the transcription factor ZEB1 is critical for CSC maintenance and function within this growth zone [17] . Indeed, multiple other epithelial-mesenchymal transition-associated transcription factors have been implicated in glioma cell invasion, and may also contribute to the maintenance of the CSC populations within white matter tracts.
CSCs of the perivascular niche
We understand far more about the CSCs of the perivascular niche than about other niche-specific CSC populations. With a few exceptions, the factors that define and maintain perivascular CSCs have been functionally linked to other cellular or extracellular components within this microenvironment. For example, Pietras et al revealed that the CD44 ligand osteopontin (OPN) is expressed within the perivascular space. CD44
+ CSCs adjacent to blood vessels bind OPN, triggering a series of molecular events that ultimately converge on the transcription of key pluripotency regulators by HIF2α [18] . Other investigators have linked the CSC phenotype to actions of integrin α6 [19] and integrin α7 [20] , and the binding of extracellular laminin within the basal lamina surrounding the brain vasculature.
The mechanism that explains how a particular marker drives the CSC phenotype within the perivascular niche is not always clear. In particular, it remains unknown whether certain CSC factors, such as CD109 or CD133, are activated by extracellular stimuli or whether these markers are purely cell-intrinsic. Shiraki et al demonstrated that the loss of CD109 compromised the CSC functions of self-renewal, proliferation, and tumourigenesis [7] . However, the mechanisms that explain this biology and the niche-specific factors to which these markers respond remain unknown. Nevertheless, it is clear that this growth zone drives CSC maintenance and provides a critical microenvironment for tumourigenesis and disease progression.
The landscape of tumour cell interactions
Shiraki et al conclude their study by describing a rare example of CSC and NSTC cooperative interaction by demonstrating that the conditioned medium from CD109 + CSCs induces proliferation of CD109 − NSTCs [7] . This finding strongly suggests that the CSCs lining the vasculature of the brain signal outwardly to drive cell division within adjacent NSTC populations ( Figure 1A [7] have revealed that CSCs expressing CD109 line blood vessels within the brains of glioma patients. Presentation of this CSC population is associated with progression from low-grade to high-grade glioma, and CD109
+ CSCs stimulate the proliferation of adjacent NSTCs. (B) Multiple interactions have been identified between CSCs, NSTCs, and non-transformed neural cell populations. These partnerships contribute to the robustness of this disease and help to drive therapeutic resistance and disease progression. New strategies that account for the dynamic complexity of the glioma microenvironment will be required to achieve durable therapeutic intervention against glioma. Reprinted with permission, Cleveland Clinic Center for Medical Art & Photography © 2017. All Rights Reserved.
cells, involving lengthy processes that physically interconnect multiple tumour cells through Cx43-mediated gap junctions. This vast network of communicating tumour cells develops throughout gliomagenesis, and enables tumour cells to support one another and resist the effects of radiotherapy [22] .
The vast majority of known pro-tumourigenic interactions within the GBM microenvironment involve non-transformed neural cell populations coopted by neighbouring tumour cells. A synthesis of this literature makes it clear that GBM tumours have the capacity, essentially, to subjugate any neural cell population to drive proliferation and disease progression ( Figure 1B ). Recent work from Venkatesh et al illustrated how synaptic neuroligin-3 could be siphoned away from cortical projection neurons to drive GBM tumour proliferation [23] . Other research has suggested that tumour-associated microglia are driven to facilitate the infiltration of tumour cells by remodelling the extracellular matrix of the brain directly ahead of invading tumour cells [24] . GBM CSCs also drive brain-resident myeloid-derived suppressor cells (MDSCs) to suppress anti-tumour immune cell activity. Consequently, the GBM tumour flourishes within a deeply immunosuppressed environment, having greatly compromised the brain's ability to mount an anti-tumour immune response [25] . Finally, multiple groups have demonstrated how tumour-associated astrocytes either actively or passively [26] facilitate tumour cell infiltration into the brain parenchyma. For example, Edwards et al described the binding of astrocyte-derived connective tissue growth factor by tumour cells expressing integrin β1, which in turn resulted in upregulation of ZEB1 and increased tumour cell invasion [27] .
Conclusions
New treatments that embrace the complexity of GBM are desperately needed, and require a deep understanding of the basic biology that propels the disease. With CD109, Shiraki et al [7] have revealed a new marker of perivascular CSCs that complements the ever-expanding list of factors that define the CSC populations within this growth zone. Further work will be required to understand the degree to which these various CSC markers identify discrete and/or overlapping populations. These authors have also identified an interesting tumour-promoting interaction between CSCs and adjacent NSTCs [7] . We now add this interaction to the set of relationships that develop within GBM tumours that serve to resist our standard therapeutic interventions. By continuing to reveal the landscape of interacting partners in various growth zones, we introduce opportunities to compromise currently unknown points of vulnerability. As our understanding deepens, we are securing a solid foundation upon which to build new therapeutics and new strategies.
